Icon Plc (ICLR) Now Covered by Analysts at Mizuho

Research analysts at Mizuho began coverage on shares of Icon Plc (NASDAQ:ICLR) in a research note issued to investors on Thursday. The firm set a “neutral” rating and a $66.00 price target on the medical research company’s stock. Mizuho’s price target suggests a potential downside of 17.65% from the stock’s previous close.

Several other analysts also recently issued reports on ICLR. SunTrust Banks, Inc. downgraded shares of Icon Plc from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $95.00 to $80.00 in a report on Friday, December 16th. Goldman Sachs Group Inc upgraded shares of Icon Plc from a “neutral” rating to a “buy” rating and upped their target price for the company from $86.00 to $90.00 in a research note on Friday, December 16th. Zacks Investment Research cut shares of Icon Plc from a “hold” rating to a “sell” rating in a research note on Tuesday, December 27th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $84.00 target price (down from $87.50) on shares of Icon Plc in a research note on Friday, January 6th. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $80.50.

Analyst Recommendations for Icon Plc (NASDAQ:ICLR)

Shares of Icon Plc (NASDAQ:ICLR) traded up 2.45% during trading on Thursday, reaching $80.15. The company had a trading volume of 398,469 shares. Icon Plc has a 52 week low of $62.31 and a 52 week high of $88.90. The stock’s 50-day moving average price is $79.82 and its 200-day moving average price is $79.69. The company has a market capitalization of $4.37 billion, a PE ratio of 17.24 and a beta of 0.63.

Icon Plc (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, February 16th. The medical research company reported $1.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.26 by $0.07. The business earned $435 million during the quarter, compared to the consensus estimate of $440.78 million. Icon Plc had a net margin of 15.60% and a return on equity of 29.47%. Icon Plc’s quarterly revenue was up 7.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.11 EPS. On average, equities analysts expect that Icon Plc will post $5.12 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Icon Plc (ICLR) Now Covered by Analysts at Mizuho” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/04/20/icon-plc-iclr-receives-new-coverage-from-analysts-at-mizuho-updated-updated.html.

Several institutional investors have recently made changes to their positions in ICLR. Legato Capital Management LLC boosted its position in shares of Icon Plc by 7,872.0% in the first quarter. Legato Capital Management LLC now owns 6,078,411 shares of the medical research company’s stock worth $76,247,000 after buying an additional 6,002,164 shares in the last quarter. WCM Investment Management CA boosted its position in shares of Icon Plc by 5.1% in the first quarter. WCM Investment Management CA now owns 3,712,253 shares of the medical research company’s stock worth $295,941,000 after buying an additional 180,896 shares in the last quarter. FMR LLC boosted its position in shares of Icon Plc by 402.9% in the fourth quarter. FMR LLC now owns 1,515,833 shares of the medical research company’s stock worth $113,991,000 after buying an additional 1,214,411 shares in the last quarter. Perkins Investment Management LLC boosted its position in shares of Icon Plc by 1,003.3% in the third quarter. Perkins Investment Management LLC now owns 729,619 shares of the medical research company’s stock worth $56,451,000 after buying an additional 663,487 shares in the last quarter. Finally, Stephens Investment Management Group LLC boosted its position in shares of Icon Plc by 5.3% in the third quarter. Stephens Investment Management Group LLC now owns 691,048 shares of the medical research company’s stock worth $53,466,000 after buying an additional 34,851 shares in the last quarter. Institutional investors own 88.14% of the company’s stock.

Icon Plc Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

5 Day Chart for NASDAQ:ICLR

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply